Antibiotic resistance (AR) poses a significant global health threat, demanding urgent attention.  Research into AR faces considerable experimental challenges, hindering the development of effective countermeasures.  One major hurdle lies in the inherent complexity of bacterial populations, exhibiting high levels of genetic diversity and adaptability, making it difficult to model resistance emergence and spread accurately *in vitro*.  Furthermore, translating *in vitro* findings to *in vivo* situations is challenging due to the multifaceted interactions within the human microbiome and host immune system, often neglected in simplified experimental models.  Developing robust and high-throughput screening methods for novel antibiotics is also problematic, given the need to identify compounds effective against resistant strains without compromising efficacy against susceptible ones.  Finally, ethical considerations surrounding human trials of novel therapies in the face of a growing public health crisis necessitate careful and rigorous experimental design, further complicating the research process.  Addressing these experimental challenges necessitates a multidisciplinary approach, combining microbiology, immunology, bioinformatics, and clinical expertise to develop more effective strategies for combating AR.